PATENT CLAIM ANALYSIS

Application Number: 16038704
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "085400"]

Abstract:
The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and/or preventing postoperative tumor recurrence and/or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and/or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

Claim (Index 516):
The method of  claim 514 , wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, local administration, and topical administration.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 95.0
- Lexical Diversity: 1.82895
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12246153', '13535291', '14656397', '15490535', '13019044']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6973799213918518
- 35 USC 102 Novelty (BERT): 0.524358766912663
- Combined Prediction Score: 0.6800778059439329
- Mean Citation Score: 295.3312160000001
- Max Citation Score: 312.7111
- Similarity Product: 195.19008924158808

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test